• Je něco špatně v tomto záznamu ?

Challenges in IgA Nephropathy Management: An Era of Complement Inhibition

V. Tesař, J. Radhakrishnan, V. Charu, J. Barratt

. 2023 ; 8 (9) : 1730-1740. [pub] 20230621

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015333

IgA nephropathy (IgAN) is the most common glomerular disease worldwide, with an estimated annual incidence of 25 per million adults. Despite optimized supportive care, some patients fail to achieve disease control and suffer progressive deterioration of kidney function. In this subpopulation of patients, the Kidney Disease: Improving Global Outcomes 2021 guidelines recommend consideration of corticosteroids; however, their use is associated with significant side effects. Ongoing clinical trials are expected to identify corticosteroid-sparing therapies to help improve treatment and prognosis for patients with IgAN. It has been well-documented that the complement system plays a significant role in IgAN pathogenesis, and several complement inhibitors are now entering late-stage clinical development. This review evaluates what we know about the role of complement in the pathophysiology of IgAN and considers how the availability of targeted complement inhibitors may impact future clinical practice. Key knowledge gaps are evaluated, and research opportunities are recommended to help guide clinical decision-making and optimize patient outcomes. Such gaps include evaluating the relative contribution of the alternative and lectin pathways to disease pathogenesis, and the importance of determining the dominant pathway driving IgAN progression. Continued research into the staining of complement proteins in kidney biopsies and identifying targeted biomarkers to assess disease progression and treatment responses will also be needed to support the implementation of newer therapies in clinical practice. Considering the future horizons for enhancing the care of patients with IgAN, tackling the outstanding challenges now will help prepare for the best possible future outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015333
003      
CZ-PrNML
005      
20231020093537.0
007      
ta
008      
231010s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ekir.2023.06.010 $2 doi
035    __
$a (PubMed)37705895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tesař, Vladimir $u Department of Nephrology, Charles University, Prague, Czech Republic
245    10
$a Challenges in IgA Nephropathy Management: An Era of Complement Inhibition / $c V. Tesař, J. Radhakrishnan, V. Charu, J. Barratt
520    9_
$a IgA nephropathy (IgAN) is the most common glomerular disease worldwide, with an estimated annual incidence of 25 per million adults. Despite optimized supportive care, some patients fail to achieve disease control and suffer progressive deterioration of kidney function. In this subpopulation of patients, the Kidney Disease: Improving Global Outcomes 2021 guidelines recommend consideration of corticosteroids; however, their use is associated with significant side effects. Ongoing clinical trials are expected to identify corticosteroid-sparing therapies to help improve treatment and prognosis for patients with IgAN. It has been well-documented that the complement system plays a significant role in IgAN pathogenesis, and several complement inhibitors are now entering late-stage clinical development. This review evaluates what we know about the role of complement in the pathophysiology of IgAN and considers how the availability of targeted complement inhibitors may impact future clinical practice. Key knowledge gaps are evaluated, and research opportunities are recommended to help guide clinical decision-making and optimize patient outcomes. Such gaps include evaluating the relative contribution of the alternative and lectin pathways to disease pathogenesis, and the importance of determining the dominant pathway driving IgAN progression. Continued research into the staining of complement proteins in kidney biopsies and identifying targeted biomarkers to assess disease progression and treatment responses will also be needed to support the implementation of newer therapies in clinical practice. Considering the future horizons for enhancing the care of patients with IgAN, tackling the outstanding challenges now will help prepare for the best possible future outcomes.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Radhakrishnan, Jai $u Columbia University Medical Center, New York, New York, USA
700    1_
$a Charu, Vivek $u Department of Pathology, Stanford University, Palo Alto, California, USA
700    1_
$a Barratt, Jonathan $u Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
773    0_
$w MED00194279 $t Kidney international reports $x 2468-0249 $g Roč. 8, č. 9 (2023), s. 1730-1740
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37705895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093531 $b ABA008
999    __
$a ok $b bmc $g 1997098 $s 1201695
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 8 $c 9 $d 1730-1740 $e 20230621 $i 2468-0249 $m Kidney international reports $n Kidney Int Rep $x MED00194279
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace